Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Marimed (MRMD) Accumulated Depreciation & Amortization (2016 - 2025)

Marimed has reported Accumulated Depreciation & Amortization over the past 10 years, most recently at $27.1 million for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 25.35% to $27.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.1 million through Dec 2025, up 25.35% year-over-year, with the annual reading at $27.1 million for FY2025, 25.35% up from the prior year.
  • Accumulated Depreciation & Amortization was $27.1 million for Q4 2025 at Marimed, up from $25.5 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $27.1 million in Q4 2025 and troughed at $462000.0 in Q1 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $12.8 million (2023), against an average of $14.0 million.
  • Year-over-year, Accumulated Depreciation & Amortization decreased 4.55% in 2021 and then soared 1553.03% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $7.0 million in 2021, then skyrocketed by 47.02% to $10.2 million in 2022, then surged by 45.89% to $14.9 million in 2023, then skyrocketed by 45.11% to $21.6 million in 2024, then increased by 25.35% to $27.1 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Accumulated Depreciation & Amortization are $27.1 million (Q4 2025), $25.5 million (Q3 2025), and $23.7 million (Q2 2025).